TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The co-presence of I148M Patatin-like Phospholipase Domain-containing 3 (PNPLA3), the rs641738 close to Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7) and the E167K Transmembrane 6 Superfamily Member 2 (TM6SF2) at-risk variants impacts on nonalcoholic fatty liver disease (NAFLD) course, in both patients and experimental models.They affect lipid droplets accumulation, mitochondrial functionality and metabolic reprogramming leading to hepatocarcinogenesis.METHODS: NAFLD patients (n ¼ 1380), of whom 121 had HCC, were stratified with a semiquantitative score ranging from 0 to 3 according to the number of PNPLA3, TM6SF2, and MBOAT7 atrisk variants.TM6SF2 was silenced in HepG2 (TM6SF2 -/-) and MBOAT7 -/-(MBOAT7 -/-TM6SF2 -/-) through Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9). RESULTS:In NAFLD patients, the additive weight of these mutations was associated with liver disease severity and an increased risk of developing HCC.In HepG2 cells, TM6SF2 silencing altered lipid composition and induced the accumulation of microvesicular lipid droplets (LDs), whereas the MBOAT7 -/-TM6SF2 -/-cells showed a mixed microvesicular/ macrovesicular pattern of LDs.TM6SF2 deletion strongly affected endoplasmic reticulum and mitochondria ultrastructures, thus increasing endoplasmic reticulum/oxidative stress.The mitochondrial number was increased in both TM6SF2 -/- and MBOAT7 -/-TM6SF2 -/-models, suggesting an unbalancing in mitochondrial dynamics, and the silencing of both MBOAT7 and TM6SF2 impaired mitochondrial activity with a shift toward anaerobic glycolysis.MBOAT7 -/-TM6SF2 -/-cells also showed the highest proliferation rate.Finally, the re-overexpression of MBOAT7 and/or TM6SF2 reversed the metabolic and tumorigenic features observed in the compound knockout model. CONCLUSIONS:The co-presence of the 3 at-risk variants impacts the NAFLD course in both patients and experimental models, affecting LD accumulation, mitochondrial functionality, and metabolic reprogramming toward HCC. (
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 2×
“TM6SF2 localizes in the endoplasmic reticulum (ER) and ER-Golgi compartments,(12) and participates in TAG-rich lipoprotein lipidation and assembly in the ER cisternae.(5,13) The rs58542926 C>T variant in TM6SF2 encoding lysine instead of glutamate at residue 167 (E167K) causes the”
BackgroundBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 3×
“The scoring of liver biopsy specimens was performed by independent pathologists unaware of patient status and genotype.(14,39) NASH was diagnosed in the presence of steatosis, lobular necroinflammation, and hepatocellular ballooning.”
BackgroundMethodResultSelf-citationStatin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390 · cited 1×
“The scoring of liver biopsy specimens was performed by independent pathologists unaware of patient status and genotype.(14,39) NASH was diagnosed in the presence of steatosis, lobular necroinflammation, and hepatocellular ballooning.”
MethodSelf-citationBianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · cited 2×
“opportunity has emerged to translate the genetics into clinics by aggregating these genetic variants in polygenic risk scores for the assessment of fatty liver development and progression.(15) However, the additive weight of the 3 at-risk mutations on liver disease severity and the related mechanisms need further inve…”
BackgroundMahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., & van't Hooft, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323785111 · Cited by 369 · cited 1×
“The overall cohort was genotyped for the rs738409 C>G (PNPLA3 I148M), rs58542926 C>T (TM6SF2 E167K), and rs641738 C>T MBOAT7 risk variants as previously described.(10,12) Genotyping was performed in duplicate using TaqMan 5’-nuclease assays (QuantStudio 3; Thermo Fisher, Waltham, MA).”
Method
Research works printed but not linked: 35
- Day, 2006, From fat to inflammation, Gastroenterology, 130, 207, 10.1053/j.gastro.2005.11.017 · DOI · Paper page
- Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
- Dongiovanni, 2015, Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis, Biomed Res Int, 2015, 460190, 10.1155/2015/460190 · DOI · Paper page
- Meroni, 2021, Genetics is of the essence to face NAFLD, Biomedicines, 9, 1359, 10.3390/biomedicines9101359 · DOI
- Mancina, 2016, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032 · DOI · Paper page
- Meroni, 2020, Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes, EBioMedicine, 52, 102658, 10.1016/j.ebiom.2020.102658 · DOI · Paper page
- Donati, 2017, MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals, Sci Rep, 7, 4492, 10.1038/s41598-017-04991-0 · DOI · Paper page
- Li, 2017, Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics, Int J Mol Sci, 18, 2550, 10.3390/ijms18122550 · DOI
- Xu, 2019, Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China, Ann Hepatol, 18, 456, 10.1016/j.aohep.2018.10.005 · DOI
- Krawczyk, 2017, Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study, J Lipid Res, 58, 247, 10.1194/jlr.P067454 · DOI · Paper page
- O'Hare, 2017, TM6SF2 rs58542926 impacts lipid processing in liver and small intestine, Hepatology, 65, 1526, 10.1002/hep.29021 · DOI · Paper page
- Prill, 2019, The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids, Sci Rep, 9, 11585, 10.1038/s41598-019-47737-w · DOI · Paper page
- Tandra, 2011, Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease, J Hepatol, 55, 654, 10.1016/j.jhep.2010.11.021 · DOI · Paper page
- Luukkonen, 2017, Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD, J Hepatol, 67, 128, 10.1016/j.jhep.2017.02.014 · DOI
- Testerink, 2009, Depletion of phosphatidylcholine affects endoplasmic reticulum morphology and protein traffic at the Golgi complex, J Lipid Res, 50, 2182, 10.1194/jlr.M800660-JLR200 · DOI
- Verkade, 1993, Impaired biosynthesis of phosphatidylcholine causes a decrease in the number of very low density lipoprotein particles in the Golgi but not in the endoplasmic reticulum of rat liver, J Biol Chem, 268, 24990, 10.1016/S0021-9258(19)74561-X · DOI · Paper page
- Krahmer, 2011, Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase, Cell Metab, 14, 504, 10.1016/j.cmet.2011.07.013 · DOI · Paper page
- Kalhan, 2011, Plasma metabolomic profile in nonalcoholic fatty liver disease, Metabolism, 60, 404, 10.1016/j.metabol.2010.03.006 · DOI · Paper page
- Li, 2011, A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease, J Proteome Res, 10, 2797, 10.1021/pr200047c · DOI
- Beyoğlu, 2013, The metabolomic window into hepatobiliary disease, J Hepatol, 59, 842, 10.1016/j.jhep.2013.05.030 · DOI · Paper page
- Min, 2014, Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells, Am J Physiol Gastrointest Liver Physiol, 307, G66, 10.1152/ajpgi.00335.2013 · DOI
- Chaurasia, 2019, Targeting a ceramide double bond improves insulin resistance and hepatic steatosis, Science, 365, 386, 10.1126/science.aav3722 · DOI · Paper page
- Rodriguez-Cuenca, 2015, Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity, Biochim Biophys Acta Mol Cell Biol Lipids, 1851, 40, 10.1016/j.bbalip.2014.09.021 · DOI
- Banini, 2021, Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis, Hepatology, 73, 1290, 10.1002/hep.31609 · DOI
- Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632 · DOI · Paper page
- Chen, 2017, The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism, Oncotarget, 8, 74209, 10.18632/oncotarget.18474 · DOI
- Luukkonen, 2016, The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans, J Hepatol, 65, 1263, 10.1016/j.jhep.2016.07.045 · DOI · Paper page
- Shen, 2014, Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects, Nat Methods, 11, 399, 10.1038/nmeth.2857 · DOI · Paper page
- Quattrini, 1996, Beta 4 integrin and other Schwann cell markers in axonal neuropathy, Glia, 17, 294, 10.1002/(SICI)1098-1136(199608)17:4<294::AID-GLIA4>3.0.CO;2-# · DOI · Paper page
- Chirambo, 2017, The role of alkaline phosphatase in intracellular lipid accumulation in the human hepatocarcinoma cell line, HepG2, Exp Mol Pathol, 102, 224, 10.1016/j.yexmp.2017.02.007 · doi:10.1016/j.yexmp.2017.02.007
- Monzio Compagnoni, 2018, Mitochondrial dysfunction in fibroblasts of multiple system atrophy, Biochim Biophys Acta Mol Basis Dis, 1864, 3588, 10.1016/j.bbadis.2018.09.018 · DOI
- Bresolin, 1985, Fatal infantile cytochrome c oxidase deficiency: decrease of immunologically detectable enzyme in muscle, Neurology, 35, 802, 10.1212/WNL.35.6.802 · DOI
- Jakobi, 2020, Sorafenib treatment and modulation of the sphingolipid pathway affect proliferation and viability of hepatocellular carcinoma in vitro, Int J Mol Sci, 21, 2409, 10.3390/ijms21072409 · DOI
- Ezzoukhry, 2012, EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib, Int J Cancer, 131, 2961, 10.1002/ijc.27604 · DOI · Paper page
Cited by
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Self-citationFan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism
Liu, J., Ginsberg, H. N., & Reyes-Soffer, G. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000930 · Cited by 19
Metadata
- Authors
- Longo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., Alisi, A., Miele, L., Soardo, G., Comi, G. P., Valenti, L., Ruscica, M., Fracanzani, A. L., Gastaldelli, A., & Dongiovanni, P.
- Venue
- Cellular and Molecular Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2022
- Volume
- 13
- Issue
- 3
- Pages
- 759-788
- ISSN
- 2352-345X (ISSN-L)
- OpenAlex
- W3215865237
- Cited by
- 112
- References
- 15
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Ministero della Salute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. https://app.cochat.ai/papers/10.1016/j.jcmgh.2021.11.007
- The paper
- Longo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., Alisi, A., Miele, L., Soardo, G., Comi, G. P., Valenti, L., Ruscica, M., Fracanzani, A. L., Gastaldelli, A., & Dongiovanni, P. (2022). TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2021.11.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.